As with most diseases, early treatment is better and decreases the risk of developing disease. If larvae do encyst in skeletal muscle cells, they can remain infectious for months to years. Primary treatment Early administration of anthelmintics, such as mebendazole or albendazole, decreases the likelihood of larval encystation, particularly if given within three days of infection. However, most cases are diagnosed after this time. In humans, mebendazole (200–400 mg three times a day for three days) or albendazole (400 mg twice a day for 8–14 days) is given to treat<unk> . These drugs prevent newly hatched larvae from developing, but should not be given to pregnant women or children under two years of age. Medical references from the 1940s described no specific treatment for<unk>  at the time, but intravenous injection of calcium salts was found to be useful in managing symptoms related to severe toxemia from the infection.. Secondary treatment After infection, steroids, such as prednisone, may be used to relieve muscle pain associated with larval migration. Vaccine research Researchers trying to develop a vaccine for Trichinella have tried to using either "larval extracts, excretory–secretory antigen, DNA, or recombinant antigen protein." Currently, no marketable vaccine is available for<unk> , but experimental mouse studies have suggested possibilities. * In one study, microwaved Trichinella larvae were used to immunize mice (orally or intraperitoneally), which were subsequently infected. Depending on the dosage and frequency of immunization, results ranged from a decreased larval count to complete protection from<unk> . * Another study used extracts and excretory–secretory products from first-stage larvae to produce an oral vaccine. To prevent gastric acids from dissolving the antigens before reaching the small intestine, scientists encapsulated the antigens in microcapsules. This vaccine significantly increased CD4+ cell levels, and increased antigen-specific serum IgGq and IgA, resulting in a statistically significant reduction in the average number of adult worms in the small intestines of mice. The significance of this approach is that, if the white blood cells in the small intestine have been exposed to Trichinella antigens (through vaccination), when an individual does get infected, the immune system will respond to expel the worms from the small intestine fast enough to prevent the female worms from releasing their larvae. * A DNA vaccine tested on mice "induced a muscle larva burden reduction in BALB/c mice by 29% in response to T. spiralis infection".
Trichinosis
Dermatomyositis
Trichuriasis
Measles
Trichiasis
Gastroenteritis
Trichomoniasis
Naegleriasis